Administered via a single intravenous infusion, the bacTRL platform has the ability to selectively colonize solid hypoxic tumors, while being cleared from healthy oxygenated tissues. This approach establishes living bio-factories within the tumors themselves, enabling consistent and accumulating gene expression levels, exclusively at the target tissues.
By doing so, Symvivo has the ability to genetically ‘re-program’ the tumors physiology to address specific therapeutic goals. This can include delivery of antigenic, cytotoxic and immuno-modulatory gene payloads, independently or in synergistic combination with one-another. This flexibility enables Symvivo to treat solid tumor(s) at the local, systemic and cellular level.
Cardiovascular injury that results in ischemic and hypoxic conditions provide a suitable environment for the bacTRL platform to colonize. This approach has the potential to deliver gene payloads that address various therapeutic aims targeting the specific requirements of the indication. These approaches include improving angiogenesis, reperfusion, anti-restenosis and endothelial protection.